PRLD Insider Trading
Prelude Therapeutics Incorporated (PRLD) operates in the Healthcare sector, specifically the Biotechnology industry, with a market capitalization near $259.7M, listed on NASDAQ, employing roughly 131 people, carrying a beta of 1.10 to the broader market. Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. Led by Krishna Vaddi, public since 2020-09-25.
In the last 12 months, Prelude Therapeutics Incorporated insiders made 6 buy transactions and 0 sale transactions.
| Date | Name | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| May 4, 2026 | Morris Charles Q | A-Award | 450,000 | $4.70 | $2.1M |
| Apr 28, 2026 | RA CAPITAL MANAGEMENT, L.P. | J-Other | 1,407,000 | $0.00 | $141 |
| Apr 28, 2026 | RA CAPITAL MANAGEMENT, L.P. | J-Other | 1,407,000 | $0.00 | $141 |
| Apr 28, 2026 | RA CAPITAL MANAGEMENT, L.P. | 0 | $0.00 | $0 | |
| Apr 23, 2026 | Bonita David P | P-Purchase | 1,689,189 | $4.44 | $7.5M |
| Apr 23, 2026 | Bonita David P | P-Purchase | 1,126,126 | $4.44 | $5.0M |
| Apr 23, 2026 | ORBIMED ADVISORS LLC | P-Purchase | 1,689,189 | $4.44 | $7.5M |
| Apr 23, 2026 | ORBIMED ADVISORS LLC | P-Purchase | 1,126,126 | $4.44 | $5.0M |
| Apr 22, 2026 | BAKER BROS. ADVISORS LP | P-Purchase | 2,137,651 | $0.00 | $214 |
| Apr 22, 2026 | BAKER BROS. ADVISORS LP | P-Purchase | 114,601 | $0.00 | $11 |
How to Read PRLD Insider Activity
Net insider sentiment is bullish over the trailing twelve months: 6 buy transactions versus 0 sales. Cluster buying by officers or directors is one of the cleaner insider signals because purchases require personal capital deployment and carry direct SEC scrutiny for material non-public information violations. The transaction table above includes the filer's reporting name, transaction type, share count, per-share price, and total dollar value where computable. For options traders, insider activity is one input to event-driven sizing alongside earnings calendar, analyst-rating cluster moves, and the implied-vol surface. Form 4 filings (the dominant Section 16 reporting form) must be submitted within two business days of the transaction; clusters of buys across multiple insiders within a short window are the strongest informational pattern. SEC EDGAR carries the underlying source filings for verification and additional historical depth.
Learn how insider trading is reported and how to read the data →
Frequently asked PRLD insider trading questions
- How active are PRLD insiders right now?
- Over the trailing twelve months, Prelude Therapeutics Incorporated (PRLD) insiders made 6 buy transactions and 0 sale transactions. Net insider sentiment over the trailing twelve months tilts to the buy side (6 buys vs 0 sales). The transaction list above shows the most recent filings; each entry includes the insider's name, transaction type, share count, and per-share price.
- What counts as an insider transaction?
- Section 16 of the Securities Exchange Act requires officers, directors, and 10% beneficial-owner shareholders to disclose changes in their holdings via Form 3 (initial statement), Form 4 (subsequent transactions, filed within two business days), and Form 5 (annual catch-up). Insider transactions cover open-market purchases and sales, exercise of stock options, gifts, and grants. The "transaction type" field on each row distinguishes these subcategories.
- Are PRLD insider buys a bullish signal?
- Insider open-market purchases (Type P) carry more informational weight than insider sales: an insider must commit personal capital, and the SEC scrutinizes purchases under Rule 10b5-1 for material non-public information. Sales, by contrast, are often driven by liquidity, tax planning, or pre-scheduled 10b5-1 trading plans rather than negative information. Cluster buying (multiple insiders buying within a short window) is a stronger signal than isolated buys.
- How do PRLD insider transactions affect options pricing?
- Insider transaction data does not directly drive implied volatility, but Form 4 disclosures can move single-name IV if the size or timing is unusual (e.g. a large CEO buy ahead of an earnings window). Options markets price the marginal informational content; routine transactions under pre-scheduled plans are typically ignored. For event-driven options sizing, pair the insider transaction history with the upcoming earnings calendar.